Skip to main content
. 2019 Oct 3;14(1):139–148. doi: 10.1093/ckj/sfz120

FIGURE 1.

FIGURE 1

Pre-emptive rituximab in patients at risk for recurrence because of the presence of nephrotic syndrome at baseline.